Distinguished in Autosomal Recessive Hypotrichosis

Jianzhong Z. Zhang

National Key Laboratory Of Intelligent Tracking And Forecasting For Infectious Diseases, 
Beijing, CN 
Distinguished in Autosomal Recessive Hypotrichosis
National Key Laboratory Of Intelligent Tracking And Forecasting For Infectious Diseases, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Jianzhong Zhang practices in Beijing, China. Zhang is rated as a Distinguished expert by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Their top areas of expertise are Atypical Pneumonia, Plaque Psoriasis, Atopic Dermatitis, Osteotomy, and Sacral Nerve Stimulation.

Their clinical research consists of co-authoring 281 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 25 articles and participated in 2 clinical trials in the study of Autosomal Recessive Hypotrichosis.

Locations

National Key Laboratory Of Intelligent Tracking And Forecasting For Infectious Diseases, Beijing, China
Other Locations
Handan, China
No. 11 Xizhimen South Street, Xicheng District, Xizhimen, 100044, China
No.11 Xizhimen South Street, Beijing, Xicheng, 100044, China
Congtai Road No. 81, Congtai District, Handan, 056000, China
Langfang, 065007, China
300399 P.R. China, Tianjin, 300399, China
Weihai, China
Liaocheng, 252000, China
State Key Laboratory Of Infectious Disease Prevention And Control, 155 Changbai Road, Changping, 102206, China
P.R. China, Yantai, 264000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-Blind, Multi-Center, Active-Controlled, Parallel-Group Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-TNFα Human Monoclonal Antibody Injection (HLX03) and Adalimumab Injection (Humira®) in Patients With Moderate to Severe Plaque Psoriasis
A Randomized, Double-Blind, Multi-Center, Active-Controlled, Parallel-Group Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-TNFα Human Monoclonal Antibody Injection (HLX03) and Adalimumab Injection (Humira®) in Patients With Moderate to Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: HLX03, Adalimumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 With Cosentyx® in Patients With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 With Cosentyx® in Patients With Moderate to Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drug: Jaktinib
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: March 14, 2025
Intervention Type: Drug
Study Drug: Jaktinib
Study Phase: Phase 3
A Randomized, Double-blinded, Placebo-controlled, Phase IIb Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized, Double-blinded, Placebo-controlled, Phase IIb Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Biological
Study Drug: AK101
Study Phase: Phase 2
A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China
A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China
Enrollment Status: Completed
Publish Date: June 28, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

281 Total Publications

Preliminary assessment of the therapeutic potential of staphylococcal enterotoxin-like W via biological activity and TCR binding sites analysis.
Preliminary assessment of the therapeutic potential of staphylococcal enterotoxin-like W via biological activity and TCR binding sites analysis.
Journal: Virulence
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile